Lithium is an agent with established neuroprotective qualities and considerable epidemiological evidence supporting its use as a dementia prophylactic. Yet it has failed to enter regular clinical use for this purpose-not for lack of evidence, but rather arguably for saturation of poor-quality evidence and aborted peripheral clinical trials. This narrative review discusses the story of lithium's almost rise to fame, and discusses future opportunities.